

30 **Abstract:**

31 Clinical data demonstrate an increased predisposition to cardiovascular disease (CVD) following
32 severe COVID-19 infection. This may be driven by a dysregulated immune response associated
33 with severe disease. Monocytes and vascular tissue resident macrophages play a critical role in
34 atherosclerosis, the main pathology leading to ischemic CVD. Natural killer (NK) cells are a
35 heterogenous group of cells that are critical during viral pathogenesis and are known to be
36 dysregulated during severe COVID-19 infection. Their role in atherosclerotic cardiovascular
37 disease has recently been described. However, the contribution of their altered phenotypes to
38 atherogenesis following severe COVID-19 infection is unknown. We demonstrate for the first
39 time that during and after severe COVID-19, circulating proinflammatory monocytes and
40 activated NK cells act synergistically to increase uptake of oxidized low-density lipoprotein (Ox-
41 LDL) into vascular tissue with subsequent foam cell generation leading to atherogenesis despite
42 recovery from acute infection. Our data provide new insights, revealing the roles of
43 monocytes/macrophages, and NK cells in COVID-19-related atherogenesis.

44

45

46

47

48

49

50

51

52

53

54

55

56 **Introduction:**

57 An increasing body of evidence suggests that coronavirus disease 2019 (COVID-19), caused by
58 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) predisposes affected
59 individuals to CVDs including acute myocardial infarction and stroke¹. Atherosclerosis is the
60 main pathophysiological process underlying most cases of CVDs in humans². It is a chronic
61 inflammatory condition which can lead to coronary artery calcification and an overall
62 prothrombotic state culminating in CVD pathology^{3,4}. Monocytes and macrophages are central
63 to the pathogenesis of atherosclerosis. Upon recruitment to the intima of arteries following lipid
64 deposition, circulating monocytes differentiate into a broad spectrum of proinflammatory
65 macrophages (M1 type), lipid-laden foam cells, and dendritic cells⁵.

66 Recent studies using coronary autopsy specimens from patients with COVID-19 revealed that
67 infiltrating macrophages are infected by SARS-CoV-2, with foam cells, a hallmark of
68 atherosclerosis at all stages of the disease, being more susceptible to SARS-CoV-2 infection
69 than other macrophages. Furthermore, SARS-CoV-2 was found to induce a strong pro-
70 atherogenic inflammatory response in both macrophages and foam cells, a phenomenon that
71 was largely recapitulated in an *ex vivo* SARS-CoV-2 infection of human vascular explants,
72 suggesting a potential mechanism for increased risk of atherosclerosis following COVID-19
73 infection⁶. Monocytes and macrophages are in constant direct and indirect (via soluble
74 mediators) communication with several other immune cells.

75 During viral pathogenesis, one of the earliest cell types to arrive at the site of infection are NK
76 cells which in partnership with monocytes/macrophages, trigger an immune response. A new
77 understanding of the functions of monocytes and macrophages in health and diseases is
78 emerging where NK cells play a crucial intermediary role⁷. The role of NK cells in “normal”
79 atherosclerosis has been described previously. However, the phenotypic and functional
80 associations of NK cells in COVID-19-associated atherosclerosis are not fully known.

81 For the first time, we demonstrate that in the peripheral blood of patients during and after severe
82 COVID-19, monocytes and NK cells are activated and may influence the consumption of
83 oxidized lipids from the circulation. This ongoing process results in the generation of foam cells
84 in vascular tissue, suggestive of persistent atherogenesis even after recovery. *In vitro*
85 experiments and correlational analyses have led to a mechanistic interpretation that suggests a
86 direct crosstalk between activated NK cells and macrophages during COVID-19, leading to an
87 increased uptake of Ox-LDL from the environment, subsequently resulting in foam cell
88 generation and atherogenesis.

89

90 **Material and Methods:**

91 **Patient characteristics:** Patients were enrolled in the Ohio State University Intensive Care Unit
92 Registry (BuckICU, IRB: 2020H0175) at the Ohio State University Wexner Medical Center and
93 the James Cancer Hospital and Solove Research Institute between April 2020 and January
94 2021. BuckICU is a multi-disciplinary biorepository project that collects human biospecimens
95 and associated clinical data from critically ill patients admitted to the ICU (severe) with
96 respiratory failure, defined as any increase in respiratory support (supplemental oxygen or need
97 for invasive or non-invasive mechanical ventilation) above baseline. For this study, we analyzed
98 samples from thirty-one critically ill patients with severe COVID-19 disease (SARS-CoV-2
99 RNA+) (n=31), between 28 and 69 years of age. Patients with current malignant diseases,
100 ongoing immunomodulatory treatment before hospitalization, and known diabetes mellitus were
101 excluded. Seventeen healthy controls (Control) that were SARS-CoV-2 immunoglobulin G (IgG)
102 seronegative and symptom-free at sampling were recruited as controls, with ages ranging from
103 25 to 65 years old. To minimize inter-experimental variability and batch effects between patients
104 and controls, all samples (n=77) were acquired, processed, and analyzed fresh during the
105 period between April 2020 and January 2021. Another group of individuals at an age range of
106 24 to 60 were recruited after three months of recovery from COVID-19 infection (n=29)

107 (Recovered) at the peak of the COVID-19 pandemic in the United States (August 2020).
108 Supplementary Table 1 and Materials and Methods both provide more specific patient
109 characteristics. To study the innate cell response, we stained fresh whole blood with a 20-color
110 innate cell–focused flow cytometry panel. All clinical laboratory analyses, including serology
111 and polymerase chain reaction (PCR) for SARS-CoV-2, were performed using clinical routine
112 assays in the clinical laboratories at The Ohio State University Wexner Medical Center,
113 Columbus, Ohio. We obtained approval by the Research Ethics Committee in The Ohio State
114 University under following IRB protocols (2020H0175, 2020H0228, 2014H0467, 2020H0339)
115 and all patients gave written informed consent. For detailed clinical information, see
116 Supplementary Table 1.

117

118 **Flow cytometry staining and Data acquisition:** Patients underwent a blood draw performed
119 by a trained phlebotomist. Peripheral blood from healthy donors and patients was collected into
120 sodium citrate tubes (BD, Franklin Lakes, NJ) and whole blood staining was performed. After
121 collection, 120µL of whole blood was separated into polystyrene FACS (fluorescence-activated
122 cell sorting) tubes and red blood cells were lysed using ACK buffer (ThermoFisher, Waltham,
123 Massachusetts) for 5 minutes followed by a wash with R10 media (RPMI-1640 supplemented
124 with 10% FBS [fetal bovine serum], 2 mM L glutamine, 100 U/mL penicillin, and 100mg/mL
125 streptomycin). After washing with phosphate-buffered saline (PBS), cells were pre-stained for
126 viability exclusion using Zombie NIR Fixable Viability dye (BioLegend, San Diego, California) for
127 10 minutes, followed by a 20-minute incubation with a panel of directly conjugated monoclonal
128 antibodies and TruStain diluted in equal parts of FACS buffer (PBS containing 0.1% sodium
129 azide and 1% bovine serum albumin) and Brilliant Stain Buffer (BD Biosciences, San Jose,
130 California). After staining, cells were fixed with 2% paraformaldehyde and were filtered by using
131 filter caps for polystyrene FACS tubes before being acquired on a Cytex Aurora, a multispectral

132 flow cytometry system with, 405-, 488-, and 640-nm lasers. Monoclonal antibodies used in the
133 panel can be accessed in Supplementary Table 2.

134 **Flow cytometry data analysis:** FCS files were exported from spectralflo software and imported
135 into FlowJo v.10.6.2 for subsequent analysis with the use of the following plug-ins to visualize
136 the data: DownSample (3.2), and t-distributed stochastic neighbor embedding (tSNE). First, the
137 compensation matrix for the 20-color flow cytometry panel was generated to correct for
138 fluorescence spillover emissions and applied to files. Dataset as such was used for the
139 downstream analysis in both manual gating (Supplementary Fig.1) and automated analysis. For
140 the automated analysis, events were first down-sampled from the CD45⁺ CD3⁻ CD19⁻ gate
141 across all samples using Down Sample. Clinical parameter categorical values for each sample
142 were added to downsampled populations as metadata to enable identification of these groups,
143 and these were then concatenated for analysis. tSNE was run using all parameters from the
144 panel except Zombie NIR (Live/Dead), BV711(CD19), FITC(CD45) and APC-Cy7 (CD3).
145 After generating the tSNE figures, manually gated immune cell subsets were overlaid to the
146 figures to represent subsets from each cohort. (e.g., 17 “healthy controls,” 31 “severe,” and 29
147 “recovered” patients). Computational analysis of flow cytometry data for monocytes were
148 visualized by uniform manifold approximation and projection (UMAP) embedding. UMAP
149 dimensionality reduction was done on the dataset using all parameters from the panel except
150 Zombie NIR (Live/Dead), BV711(CD19) FITC(CD45) and APC-Cy7 (CD3). The data were
151 projected in 2-dimensions using UMAP embeddings and clusters of major monocyte subsets
152 were identified based on expression of lineage defining markers. We used R (version 4.2.1) with
153 packages ggpubr, ggplot, psych, gridExtra, corrplot^{8,9} to generate figures.

154

155 **Measurements of inflammatory biomarkers, chemokines, and cytokines:** The plasma
156 collected from blood samples was stored at -20°C and batched until processing without a prior
157 thaw. Using enzyme-linked immunosorbent assay (ELISA), the following inflammatory markers

158 were measured (Supplementary Table 3) including: Tissue inhibitor of metalloproteinases-1
159 (TIMP-1), Tissue inhibitor of metalloproteinases-2 (TIMP-2), Monocyte chemotactic protein 1
160 (MCP-1), Lipoprotein-Associated Phospholipase A2 (LpPLA2), oxidized low-density lipoprotein
161 (Ox-LDL). To detect plasma cytokine and chemokine levels, plasma samples were processed
162 using the multiplexed ELISA-based platform Quantibody® Human Inflammation Array 3
163 (RayBiotech QAH-INF-3) in accordance with the manufacturer's protocol. Raw optical data were
164 analyzed using the manufacturer's analysis tool to construct standard curves and determine
165 absolute cytokine concentration.

166

167 **In-vitro Ox-LDL uptake experiment:** An in-vitro experiment was conducted to investigate the
168 role of activated NK cells in the uptake of Ox-LDL by macrophages. 5ml of venous blood
169 samples were collected from severe COVID-19 patients (n=6) in sodium citrate tubes, and
170 Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll gradient centrifugation.
171 The isolation of NK cells was performed using the Miltenyi Biotec NK cell isolation kit (130-092-
172 657). Subsequently, NK cells were activated *in vitro* through incubation with autologous plasma.
173 Concurrently, PBMCs were allowed to rest and were incubated in Teflon-coated wells for up to
174 six days. This incubation stimulated the development of monocyte-derived macrophages
175 (MDMs) from peripheral blood monocytes¹⁰. After six days, these monocyte-derived
176 macrophages were exposed to a medium containing Ox-LDL, which had been commercially
177 manufactured and dye-tagged with Dil, to assess the absorption of Dil-Ox-LDL (10 ug/mL). This
178 assessment was carried out after a four-hour incubation period in the presence or absence of
179 plasma-activated NK cells. The cells were subsequently washed twice with PBS, and the
180 intensity of Dil staining was measured using flow cytometry. To identify macrophages, markers
181 such as CD45, CD3, CD19, and CD14 were utilized. For fluorescence microscopy analysis, the
182 cells were seeded into 12-well plates and incubated at 37°C for an additional 24 hours. Images

183 were acquired using an EVOS microscope, and the presence of Dil was detectable using an
184 RFP filter (absorption peak: ~554 nm, emission peak: ~571 nm).

185 **scRNA-seq data analysis:** scRNA-seq data were obtained from a published dataset¹¹ The data
186 file (in 'rds' format) downloaded from the cellxgene Data Portal ([https://cellxgene.Cziscience](https://cellxgene.cziscience.com/datasets)
187 [.com /datasets](https://cellxgene.cziscience.com/datasets)) were read into R (version 4.2.1) session. Quality control was performed using
188 Seurat (v3.1.5) to identify and filter out low-quality cells based on mitochondrial content and
189 performing data preprocessing to prepare the data for downstream analysis. Cells with a
190 percentage of mitochondrial genes greater than 10% were considered low quality and were
191 filtered out. Prior to downstream analysis, the dataset was scaled and centered using
192 "NormalizeData" and "ScaleData" functions. As the focus was on NK cells and monocytes and
193 comparison between severe and control groups, specific subsets of scRNA-seq data set were
194 separated and merged based on their metadata. The reanalysis included the standard Seurat
195 workflow with "RunPCA" and the number of Principle component analysis (PCA) dimensions
196 used was 30, with a resolution parameter of 0.5. An elbow plot was generated to determine the
197 optimal number of principal components for downstream analysis. UMAP plots were generated
198 to visualize the cell clusters and identify potential subpopulations. After the cell clusters had
199 been obtained, the Differentially expressed genes (DEG) in each cluster was computed with
200 'FindAllMarkers' (Supplementary Table 4)^{12,13}. Marker genes were determined based on their
201 average log-fold change (log₂FC) and statistical significance (p-value and q-value).

202 Gene Ontology (GO) enrichment analysis was performed to gain insights into the biological
203 processes associated with a set of genes of interest. The analysis was carried out using the
204 clusterProfiler package in R (version 4.2.1)¹³. The significance threshold for enriched GO terms
205 was set at a p-value cutoff of 0.05, and the Benjamini-Hochberg method was applied for multiple
206 testing correction using GO terms with a q-value (adjusted p-value) below 0.05 were considered
207 statistically significant. Cytoscape software (version 3.10.0) was used to visualize significant
208 GO terms and integrate the GO terms to create a GO pathway network. For the DEGs, Kyoto

209 Encyclopedia of Genes and Genomes (KEGG) pathway enrichment was performed for the top
210 200 DEGs. Enrichment analysis of the converted Entrez IDs was conducted to determine the
211 significant KEGG pathways associated with the DEGs. The enrichKEGG function from the
212 clusterProfiler package was utilized, specifying the gene IDs and the organism of interest (Homo
213 sapiens, organism code 'hsa')¹⁴. This function identified overrepresented pathways based on a
214 hypergeometric test. We employed the cnetplot function, to show the hub genes and pathways
215 enriched.

216

217 **Statistical Analysis:** Graphs and heatmaps were prepared using GraphPad Prism, version 9.
218 Data were statistically analyzed using their bundled software. One-way ANOVA¹⁵ was used to
219 compare three or more groups followed by Dunn's multiple comparisons test for pairwise
220 comparisons. Comparisons between two groups were performed using the Wilcoxon rank-sum
221 test. To analyze the relationship between immune signatures and plasma biomarkers, Pearson
222 correlation coefficient was calculated and plotted on a correlogram using R 4.2.1. Scatter plots
223 showing linear relationships between data were created for significant correlations. Data
224 visualization was achieved using functions from the Seurat, ggplot2, and pheatmap packages.

225

226 **Results:**

227 **Study design and cohort demographics:** In this cross-sectional study, we assessed the
228 immune profile in fresh whole blood samples from patients across three groups: 1) healthy
229 donors: seventeen healthy age/sex-matched adults (n=17) who were SARS-CoV-2
230 immunoglobulin G (IgG) seronegative and asymptomatic at sampling as controls, 2) patients
231 with severe COVID-19: thirty-one patients (n=31) with sampling on day one of intensive care
232 unit admission for severe COVID-19 and respiratory failure, and 3) recovered patients: twenty-
233 nine individuals with complete clinical recovery (n = 29) sampled three months after severe
234 COVID-19 infection. Supplementary Table 1 and Materials and Methods both provide more

235 specific patient characteristics. To minimize inter-experimental variability between patients and
236 controls, all samples (n=77) were acquired, processed, and analyzed fresh between April 2020
237 and December 2020. Samples were analyzed using a 20-color spectral flow cytometer
238 (Supplementary Table 1, gating strategy in Supplementary Fig.1).

239

240 **Temporal dynamics of innate immune signatures and dysregulations in severe COVID-**

241 **19:** We applied conventional flow cytometry and tSNE dimensionality reduction plots gated on
242 CD45⁺CD3⁻CD19⁻ cells, which allowed for the identification and visualization of 10 innate
243 immune cell populations (Fig.1A). The clustering algorithm allowed for an unbiased
244 representation of these clusters during each stage of the disease. Among the dominant innate
245 cell subsets that were focused on this study, we observed a significant increase in the
246 frequencies of eosinophils (p<0.05) and neutrophils (p<0.05) among severe covid-19 patients
247 (Fig.1B). While no differences were observed in the frequency of total monocytes between the
248 control and severe groups, an overall increase in their frequencies was observed following
249 recovery (p<0.05). Total NK cell frequencies were significantly decreased during severe
250 infection and returned to basal levels after recovery, similar to previously published data¹⁶. We
251 next analyzed the connectivity of cellular profiles and cytokine levels (detailed in Fig.2) in each
252 study group. Heatmaps depicting correlation between 48 plasma cytokines/chemokines and 10
253 major innate immune cell subsets for the control, severe and recovered groups constructed
254 based on Pearson correlation coefficient (Fig.1C). The correlation coefficients between those
255 cell subsets were used to construct the density plot for each group. The density plot for Pearson
256 correlation coefficients between three groups (control, severe, and recovered) comparing
257 immune cell and cytokine data, provides a visual representation of the distribution of correlation
258 coefficients for various pairs of variables between these groups (Fig.1D). Each line on the
259 density plot represents one of the groups, and the plot can help reveal central tendency, spread
260 and variability. A higher peak indicates a stronger central tendency toward certain correlation

261 values. Visually comparing the three density lines, you can assess differences or similarities in
262 the correlations between the groups. Comparing the three group's density lines, we observe a
263 greater overlap between severe and recovered group, compared to controls. Overall, the
264 correlograms and density plots imply that the recovered donor group has a more similar
265 distribution to severe patients than to the controls. PCA also revealed that three groups have
266 differential cellular and cytokine profiles (Fig.1E). The volcano plot (Fig.1F) visualizes a
267 sustained dysregulation of immune and biochemical parameters despite recovery from the
268 disease. Overall, our data suggest that severe COVID-19 patients' innate cell responses are
269 dysregulated, with some immune perturbations persisting even after assumed viral clearance
270 and recovery (up to 90 days post-infection).

271

272 **Differential inflammatory and cardiovascular biomarker profiles following severe COVID-**

273 **19:** Next, we analyzed 48 cytokines, chemokines, and plasma biomarkers related to
274 cardiovascular risk, including those associated with the 'cytokine storm' and post-acute
275 sequelae of SARS-CoV-2 infection, in plasma samples (Fig.2A). Interestingly, seven of 33
276 increased cytokine responses in the severe patients were also increased in the recovered
277 population. Nine cytokines were decreased in severe patients and the recovered donors
278 compared to levels in the healthy donors (Fig.2A). For a broader comparative analysis of
279 proinflammatory protein profiles that exhibited differential expression among our study cohorts,
280 we executed PCA on all the proteins identified in the plasma (Fig.2B). The control, severe, and
281 recovered groups displayed distinct clustering, signifying significant dysregulation of
282 inflammatory proteins both during and after severe COVID-19 infection. Interestingly, our
283 findings reveal that metalloproteinase inhibitors, specifically TIMP-1 and TIMP-2, which are
284 recognized for their pivotal roles in atherosclerosis, plaque development, and platelet
285 aggregation¹⁷, were elevated in severe patients (Fig.2C and Fig.2D) and persisted even three
286 months after recovery from severe COVID-19. We also found increased levels of MCP-1

287 (Fig.2E), which is known to mediate migration and infiltration of monocytes to tissues, in severe-
288 COVID-19 patient's plasma. We also found an increase in Interferon-gamma inducible Protein
289 10kDa (IP-10) (Supplementary Fig.2A), and decreased levels of CCL5/RANTES (Regulated on
290 activation, normal T cell expressed and secreted) (Supplementary Fig.2B) and eotaxin
291 (Supplementary Fig.2D) in severe patients compared to levels in the other groups. Levels of
292 cardiometabolic and inflammatory biomarkers, including soluble CD14 (sCD14),
293 lipopolysaccharide-binding protein (LBP), fatty acid binding protein 4 (FABP4), D-Dimer, C
294 reactive protein (CRP), and tissue factor (Supplementary Fig.2), were elevated during severe
295 disease, but levels in healthy and recovered participants were similar (Supplementary Fig.2).
296 Notably, CRP and D-dimer levels, indicative of COVID-19 severity, may correlate with
297 complications like acute respiratory distress syndrome (ARDS) and cardiovascular events.
298 Unexpectedly, levels of Ox-LDL and LpPLA2 were decreased in severe and recovered patients,
299 compared to levels in healthy controls (Fig.2F-G). This surprising finding highlights a persistent
300 disruption in mechanisms involving modified lipoprotein homeostasis during and after severe
301 COVID-19 infection.

302

303 **Monocyte subset dynamics in COVID-19: Implications for immune dysregulation.** Next,
304 we examined monocyte subsets in our study populations. We observed elevated levels of
305 CD14⁺⁺CD16⁻ "classical" monocytes in the recovered donors' whole blood compared to the
306 other two groups (Fig.3A and B). In contrast, intermediate monocytes (CD14⁺⁺CD16⁺) were
307 increased in severe patients (Fig.3B), while the frequency of CD14⁻CD16⁺ "non-classical"
308 monocytes was reduced in severe COVID-19 patients. Monocytes were visualized in a two-
309 dimensional space using UMAP in Flowjo 10.9.0 (Fig.3C), which showed unique sub-clusters
310 depending on the disease condition. Control and recovered groups had similar clustering
311 patterns, distinct from the severe group, and some island clusters exhibited differences,
312 suggesting varying features between these cohorts. No statistically significant changes were

313 observed in CD27, CXCR3, and PD-1 receptor expression in classical and intermediate
314 monocytes. However, the trend for decreased expression in PD-1 and increased CXCR3
315 expression in non-classical monocytes in the severe COVID-19 group suggests a more
316 proinflammatory phenotype displayed by this subset (Fig.3D and Supplementary Fig.3C). We
317 noted significant increases in CXCR5-expressing intermediate monocytes among our study
318 populations compared to controls, with elevated frequencies persisting from severe disease into
319 the recovery phase (Fig.3D and E). Similar monocyte/macrophage subsets have previously
320 been reported in atherosclerotic lesions¹⁸. In contrast, severe COVID-19 patients exhibited low
321 levels of intermediate and classical monocytes expressing tissue residency markers (e.g.,
322 CD69) in their peripheral circulation, and this reduction was also seen in the recovered group
323 ($p<0.05$) (Fig.3D, and F). Our results indicate persistent dysregulation of circulating monocytes
324 post-COVID-19 recovery, involving alterations in frequencies, subsets, and functional markers.

325

326 **Dysregulated NK cell phenotypes associated with COVID-19 infection.** We and others have
327 observed that COVID-19 infection alters total NK cell frequencies in peripheral blood^{16,19}. Using
328 a previously described gating strategy, CD56 and CD16 receptor expression were used to
329 identify five distinct NK cell subsets²⁰ (Fig. 4A and B). NK cell subsets clustered differently
330 among the three groups. Overall, patients with severe illness had considerably lower
331 frequencies of all five NK cell subsets (Fig.4D). Furthermore, these subsets showed noticeable
332 differences between groups in terms of expression of activation and tissue homing markers
333 (Supplementary Fig.4). In all NK subsets, CD69, a marker of activation and tissue residency²¹
334 was increased in individuals with severe COVID-19. Levels of CD69 on NK cell subsets was
335 similar between healthy and recovered donors (Fig.4F). We also noted an increasing trend in
336 HLA-DR expression during severe infection, suggesting NK cell activation during severe
337 disease (Fig. 4G). Additionally, NKG2A expression (indicating an inhibitory NK phenotype)²²
338 was decreased among NK subsets in severe COVID-19 patients (Supplementary Fig.4B),

339 confirming NK cell activation during severe infection. We also noted significantly lower
340 expression of CD27 in three of the NK subsets except CD56^{dim}CD16⁻ and CD56⁻CD16^{dim}
341 subsets in severe COVID-19 patients and recovered donors compared with controls (Fig.4E).
342 CD27⁺ NK cells are particularly important in mediating NK cell /T cell interaction via the CD27-
343 CD70 pathway²³.

344

345 **Implications of activated NK cells and monocytes on Oxidized LDL levels and potential**

346 **atherogenesis in severe COVID-19:** In order to determine whether the changes we observed

347 in innate cells were related to cardiometabolic biomarker levels, we performed Pearson

348 correlational analysis to assess associations between plasma biomarker data acquired through

349 ELISA and flow cytometry immune cell frequencies. As shown in Fig.2F and G, while most

350 biomarkers returned to basal levels after recovery, Ox-LDL and LpPLA2 (which co-traffics Ox-

351 LDL into tissue) levels remained decreased significantly even after recovery. Ox-LDL is

352 recognized as a key player in the development of atherosclerosis (atherogenesis)²⁴. We

353 identified multiple correlations between immune cell data and plasma Ox-LDL (Fig.5A and B).

354 We discovered a strong negative correlation between CD69⁺ NK cells and Ox-LDL levels

355 (Fig.5C-D and Supplementary Fig.5A-D) as well as a negative correlation between Ox-LDL and

356 activated (CD69⁺) total monocytes (Fig.5F), activated (CD69⁺) classical monocytes (Fig.5G) and

357 intermediate monocytes (Fig.5H) among our severe COVID-19 patients. Monocytes migrate into

358 the arterial wall and differentiate into macrophages, where these cells can internalize Ox-LDL

359 and transform into foam cells²⁵. Therefore, our findings suggest a novel mechanism underlying

360 the reduction of Ox-LDL levels in severe COVID-19 patients, potentially driven by activated NK

361 cells contributing to increased consumption of Ox-LDL from the circulation by MDMs, leading to

362 increased foam cell formation and subsequent atherogenesis in COVID-19 patients.

363

364 **Transcriptional profiling and functional differentiation of monocytes and NK cells in**
365 **severe COVID-19:** We validated the phenotypic changes observed in flow cytometry and
366 plasma biomarker assays using a publicly available single-cell RNA sequencing (scRNA-seq)
367 dataset from Schulte-Schrepping et al.¹¹ For both NK cells and monocytes, we identified 2307
368 and 1815 DEGs (adjusted p-value < 0.05 & positive log₂FC) (Supplementary Fig.6A), selecting
369 the top 200 DEGs for GO enrichment analysis (Supplementary Table 4 and 5). UMAP figures in
370 Supplementary Fig.6B showcased immune cell annotations and clustering based on disease
371 condition (control vs. severe COVID-19), with DEG analysis separately conducted for NK cells
372 and monocytes. Heatmaps in Supplementary Fig.6C (monocytes) and Fig.6D (NK cells)
373 provided an overview of transcriptional profile differences. Our analysis, incorporating the top
374 200 DEGs, revealed that transcriptional profiles phenotypically and functionally distinguished
375 severe COVID-19 patients from uninfected counterparts. Volcano plots (Supplementary Fig.6D
376 and E) displayed upregulated (red) and downregulated (green) genes. Our flowcytometry
377 analysis revealed that severe patients and recovered donors both exhibited an increased
378 presence of intermediate monocytes (as shown in Fig.2B). This difference was found to be
379 statistically significant (p<0.05). Incidentally, our transcriptome analysis revealed an
380 upregulation of *CD36*, a gene known to be more expressed in intermediate monocytes. *CD36*
381 encodes a receptor for Ox-LDL, and it plays a role in binding and internalizing Ox-LDL.
382 Additionally, our analysis predicted multiple epigenetic modifications occurring as a result of
383 severe infection. This prediction was corroborated by a high number of DEGs associated with
384 histone modification and DNA methylation. Examples of these genes include *H1-4*, *H1-3*, *H1-10*,
385 *H1-2*, and *SETD2* (Supplementary Table 4). In monocytes, we observed significant
386 upregulation in expression of *CXCL2*, *IL1b* and *NLRP3* other notable genes suggestive of a
387 proinflammatory phenotype in monocytes. (Fig.6A & Supplementary Table 4). Similarly, in NK
388 cells, we detected upregulation of genes indicative of migration, inflammation, and activation,
389 including *ICAM3*, *TNFAIP3*, *CD69*, and *IL12RB1* (Fig.6B & Supplementary Table 4). Some

390 genes like *ICAM3*, *TNFSF12*, *TNFSF1214*, *NLRP3* and *BRD2* were upregulated in both cell
391 types (Supplementary Table 4).

392

393 **Pathway analysis reveals intriguing interplay between viral response and lipid storage**

394 **regulation in macrophages, highlighting persistent changes in innate cells:** Furthermore,

395 we conducted GO enrichment analysis to explore the functional enrichment of the DEGs, and

396 the KEGG database was used to group these differentially expressed genes into gene

397 pathways. We utilized the GO database and considered GO terms with a p-value < 0.05

398 significantly enriched (Fig6C-D & Supplementary Table 5). Our analysis revealed significant

399 enrichment in GO terms associated with lasting cellular epigenetic changes. This pattern was

400 consistent in both NK cells and monocytes during severe infection. Both cell types showed

401 enriched pathways related to dysregulated unfolded protein response, particularly regulation of

402 endoplasmic reticulum (ER) stress. In monocytes, we found significant enrichment in GO terms

403 like "leukocyte chemotaxis", "myeloid leukocyte migration", and "phagocytosis engulfment",

404 suggesting potential activation and differentiation of migratory, phagocytic macrophages. In NK

405 cells, GO pathway analysis highlighted the importance of "defense response to virus" and "viral-

406 induced Pattern recognition receptor (PRR) pathway signaling" in combating SARS-CoV-2

407 infection.

408 Interestingly, we observed an overlap between DEGs and enriched GO terms in NK cells and

409 monocytes. Genes like *STAT*, *TNFAIP3*, and *NFKBIA* were differentially expressed and

410 enriched in multiple GO terms. We used Cytoscape v3.10.0 to create network visualizations of

411 enriched GO pathways for monocytes (Fig.6E) and NK cells (Fig.6F). The monocyte network

412 has 57 nodes, while the NK cell network has 39 nodes, each representing a specific GO

413 pathway. The edges between nodes indicate potential relationships between pathways based

414 on shared genes. Lighter node colors indicate greater statistical significance for pathway

415 enrichment. Connections between pathways in the network imply shared genes, suggesting

416 possible crosstalk or cooperation in biological processes. Node color signifies pathway
417 enrichment significance, and lighter shades indicate stronger significance. Edges represent
418 shared genes, hinting at potential functional links, like crosstalk or cooperation between
419 pathways due to shared genes in biological processes. In monocytes, a significant network
420 emerges with interconnected pathways such as macrophage activation, phagocytosis, ER
421 stress, acute inflammatory response, and lipid storage regulation. This network has the potential
422 to fuel atherogenesis through immune system activation. A prominent connection arises in NK
423 cells between defense response to viruses, PRR signaling, and stem cell differentiation
424 regulation. This suggests that NK cells, when encountering viruses, adopt an activated
425 migratory phenotype, potentially becoming dominant in circulation. Furthermore, the KEGG
426 pathway analysis (Supplementary.Fig.6G-H) adds another layer of evidence to the notion of
427 enduring alterations in innate cells and their potential impact on the post-acute consequences of
428 SARS-CoV-2 infection. The amalgamation of differential gene expression and GO enrichment
429 analysis offers a holistic understanding of the molecular terrain associated with severe COVID-
430 19 and the enduring modifications in innate cells. This insight can potentially reveal valuable
431 biomarkers and therapeutic targets for further exploration.

432

433 **Enhanced Ox-LDL uptake by monocyte-derived macrophages in the presence of**
434 **autologous NK cells treated with plasma from severe COVID-19 patients:** Based on our
435 observations of innate immune responses and plasma biomarkers in vivo and analysis of
436 published single-cell data, we have identified a significant correlation between multiple activated
437 NK cell subsets and plasma Ox-LDL. Our findings strongly imply that these activated NK cells
438 play a pivotal role in enhancing the uptake of circulating Ox-LDL. To further investigate the
439 contribution of activated NK cells to atherogenesis and substantiate our hypothesis, we
440 conducted an in vitro experiment to explore the impact of activated NK cells on Ox-LDL uptake
441 by macrophages (Fig.7A).

442 We employed a method as outlined in one of our earlier publications. Frozen PBMCs from
443 severe COVID-19 patients (n = 6) were used to isolate NK cells. These NK cells were
444 subsequently incubated with autologous plasma. Concurrently, autologous MDMs were
445 generated from the same patient's PBMCs by allowing them to rest in Teflon-coated wells for up
446 to six days. Following a six-day incubation period, we incubated these MDMs for four hours with
447 commercially manufactured Dil-labeled Ox-LDL, both in the presence or absence of activated
448 autologous NK cells. Interestingly, we observed significantly higher Dil-Ox-LDL uptake in the
449 presence of activated NK cells (Wilcoxon signed rank-test; $p < 0.05$ for all) (Fig.7B and C). The
450 levels of Dil-Ox-LDL were quantified using flow cytometry, and this was further confirmed
451 through EVOS microscope images (Fig.6D). Microscopic images were acquired to detect cells
452 with internalized Dil-Ox-LDL using an RFP/TRITC filter set (absorption peak: ~554 nm,
453 emission peak: ~571 nm). In summary, our findings collectively suggest that activated NK cells,
454 in conjunction with other plasma factors, may be linked to increased Ox-LDL uptake and
455 increased cardiovascular risk in individuals with severe COVID-19.

456

457 **Discussion:**

458 The COVID-19 pandemic has shed light on a range of health concerns beyond acute respiratory
459 symptoms of the disease, including atherosclerotic cardiovascular disease. Given that evidence
460 from genome-wide association studies, imaging techniques and clinical intervention studies
461 confirm innate immune involvement in accelerating atherosclerosis²⁶, it is likely that the immune
462 perturbations following SARS-CoV-2 infection may be a key driver in COVID-19 associated
463 CVDs. Our study provides mechanistic evidence to support the importance of unique
464 macrophage-NK crosstalk during severe COVID-19 infection in promoting long-term
465 atherogenesis. We show that in the proinflammatory environment of severe COVID-19, subsets
466 of NK cells with altered phenotypes help macrophages take up modified lipids (Ox-LDL) and
467 enhance foam cell generation. Our study also highlights a persistence of the pro-atherogenic

468 potential following recovery from severe COVID-19, as evidenced by these innate immune
469 alterations and disturbances in cardiometabolic biomarkers persisting up to three months after
470 recovery.

471 Monocytes and macrophages play a crucial role in the development of atherosclerosis, both as
472 mediators of chronic inflammation and plaque generation through lipid uptake²⁷. Monocytes
473 migrate from the bloodstream to the vessel wall, where they transform into tissue macrophages.
474 These tissue macrophages subsequently convert into foam cells by taking up modified
475 cholesterol, in particular Ox-LDL, initiating atherogenesis²⁸. Our observations of significant
476 increases in circulating intermediate monocytes in our severe COVID-19 patients (and
477 remaining elevated post-recovery) suggests that atherogenesis may occur more readily during
478 and after severe COVID-19 infection, as proinflammatory monocyte subsets such as these have
479 a greater potential for trans-endothelial migration and vessel wall adhesion⁵. Increased CXCR5
480 expression in this monocyte subset among both severe COVID-19 patients and those who
481 recovered further enhances their chemotactic potential towards inflamed vascular intimal tissue
482 rich in its ligand CXCL13²⁹. In addition, we noted elevated levels of other chemokine ligands like
483 MCP-1³⁰ in the plasma of severe COVID-19 patients. This may be a valid explanation to our
484 observations of decreased CD69-expressing intermediate (tissue-resident) monocytes in the
485 circulation of severe COVID-19 patients. Simultaneous reductions in Ox-LDL and LpPLA2
486 during severe infection, persisting even after recovery may indicate ongoing consumption of
487 these atherogenic mediators. This may suggest that these intermediate monocytes leaving the
488 circulation to transform into intimal macrophages may play a role in Ox-LDL consumption.

489 Contradicting evidence suggest that in COVID-19 patients, during early recovery, higher levels
490 of Ox-LDL are likely to be observed³¹. However, these studies did not account for other risk
491 factors of atherosclerosis and those which dysregulate lipid metabolism, including diabetes
492 mellitus and hypertension. Considering the fact that we excluded majority of these factors
493 suggest their exclusion may influence the outcome of our data which shows the onset of

494 atherogenesis and role of Ox-LDL uptake in its early stages. Our analyses of transcriptome
495 data from PBMCs of severe COVID-19 patients from external databases support our high-
496 dimensional flowcytometry analyses, revealing enrichment in transcriptional pathways
497 supporting chemotaxis, migration, phagocytosis, plasma membrane invagination, and
498 engulfment, and upregulation of DEGs encoding macrophage scavenger receptors like CD36,
499 SR-A and those involving lipid storage.

500 Monocytes/macrophages are the most investigated immune cells in atherosclerosis. However,
501 there is now increasing preclinical and clinical evidence that NK cells play a significant role in its
502 pathogenesis. Traditionally considered immune defenders against viruses^{32,33} and cancer³⁴, this
503 heterogenous group of immune cells are now increasingly recognized for their diverse roles,
504 including those related to disease pathogenesis. In the case of human atherosclerosis, most of
505 the current knowledge on NK cell involvement comes from observational studies on
506 atherosclerotic lesions using immunohistochemistry. Bonaccorsi et al. characterized NK cells in
507 atherosclerotic plaques of asymptomatic patients and found that these were enriched in
508 CD56^{bright}perforin^{low} NK cells, which also expressed tissue-resident markers such as CD69³⁵.

509 While we and others have shown overall reductions in circulating NK cells during acute COVID-
510 19¹⁶, we have also seen significantly increased expression of CD69 in these NK cells and their
511 strong negative association with plasma Ox-LDL, suggesting that these NK cells may be linked
512 to processes involving uptake of Ox-LDL from the circulation into tissue. Cytokines like TNF α ,
513 among the other proinflammatory cytokines that likely flood the circulation during the cytokine
514 storm of acute severe COVID-19, are known to be key modulators of NK cell cytotoxicity,
515 cytokine production, and adhesion molecule upregulation, and influences receptor expression,
516 including activating receptors like NKG2D and CD69. As evidenced by our NK cell
517 transcriptional analysis showing enrichment of the chemokine signaling pathway, these
518 activated NK cells may be increasingly recruited to inflamed tissue to eliminate infected cells³⁶.

519 However, excessive NK cell activation can also promote tissue damage and inflammation.

520 Within this microenvironment, macrophages are reported to express NKG2D ligands (such as
521 Major Histocompatibility Complex class I chain-related proteins A, MICA) suggesting the
522 potential for direct macrophage-NK cell interactions. These interactions are known to promote
523 macrophages to differentiate into proinflammatory M1 phenotype³⁷.

524 Netea et al. demonstrated that, in addition to microbial stimuli, endogenous metabolites, such as
525 Ox-LDL, that are abundant in the plaque microenvironment, train pro-atherogenic monocytes
526 and macrophages, possibly via epigenetic modifications which may be the key driver leading to
527 ongoing atherogenesis despite recovery from acute SARS-CoV-2 infection³⁸. This would
528 substantially increase future CVD risk in previously infected individuals. Analysis of single cell
529 transcriptome data of monocytes and NK cells found enriched pathways related to histone
530 modifications, crucial for epigenetic changes, further confirming the possibility of trained
531 immunity following severe COVID-19 infection.

532 Within vascular intimal tissue, hydrolysis of Ox-LDL into oxidized fatty acids contribute to
533 endothelial dysfunction, inflammation, and foam cell formation which may alter vascular
534 architecture³⁹. Progressive atherogenesis and vascular remodeling, reflected by persistent
535 elevations in plasma TIMP-1 and TIMP-2 despite recovery⁴⁰ is likely to contribute to the
536 increased thromboembolic events documented following acute severe COVID-19 which has
537 drawn significant scientific interest⁴¹. Indeed, Severe COVID-19 patients in our study showed a
538 likely procoagulant state, evident from significantly elevated D-dimer levels, a marker of
539 thromboembolic disease severity⁴². While the procoagulant state in COVID-19 is complex⁴³, our
540 study suggests that unique dysregulations in monocyte/macrophage and NK cell activity may
541 contribute to thrombosis, by damaging the endothelium, promoting atherogenesis, and
542 disrupting wall architecture. This interpretation aligns with the classical Virchow's triad, which
543 describes factors contributing to thrombosis. NK cell infiltration in particular may additionally
544 damage the endothelium and disrupt wall architecture via perforin and granzyme B⁴⁴ and

545 elevate tissue factor levels (as seen in our severe COVID-19 patients), initiating the coagulation
546 cascade by combining with activated factor VII⁴⁵.

547 Our study is limited to the analysis of a small, cross-sectional cohort of individuals with severe
548 COVID-19 infection. Furthermore, all samples were collected during the early phases of the
549 COVID-19 pandemic, and thus our findings are pertinent only to the SARS-CoV-2 strains that
550 circulated during that time in a pre-vaccination timeframe. Despite these limitations, our study
551 provides a novel perspective on the pathophysiological events driven by monocytes and NK
552 cells during severe COVID-19. These events ultimately contribute to atherogenesis and
553 coagulopathy, leading to enduring cardiovascular and thromboembolic disease risks. The
554 insights gained from this research pave the way for future therapeutic strategies aimed at
555 mitigating COVID-related cardiovascular and thromboembolic events by targeting these
556 mechanistic pathways.

557

558 **Acknowledgments:**

559 The authors gratefully acknowledge the support of all study individuals and their families. This
560 work was partially supported by National Center for Advancing Translational Sciences
561 (KL2TR002734 and UL1TR002733 to [J.S.B.]). We also, like to thank Sarah Karow and
562 Gabrielle Swoope for their efforts in sample collection and clinical coordination.

563

564 **Author Contribution:**

565 M.G, Y.W and M.A performed experiments, data analysis and, wrote the manuscript. E.B, J.G
566 and A.K, performed lipid biomarker experiments. A.V. and A.K, performed cytokine experiments
567 and edited the manuscript. J.H, S.S, S.P, S.L and J.B coordinated clinical sample collection and
568 edited the manuscript. D.K and K.W. supervised data analysis, S.W and M.G performed
569 transcriptome data analysis, N.F supervised lipid biomarker experiments and wrote the
570 manuscript, T.D, and N.L designed the study and wrote the manuscript.

571

572

573 **Data Availability:**

574 The data that support the findings of this study are available from the corresponding author
575 upon reasonable request.

576

577

578 **References:**

- 579 1 Kunutsor, S. K. & Laukkanen, J. A. Cardiovascular complications in COVID-19: A
580 systematic review and meta-analysis. *J Infect* **81**, e139-e141,
581 doi:10.1016/j.jinf.2020.05.068 (2020).
- 582 2 Vilaplana-Carnerero, C. *et al.* Atherosclerosis, Cardiovascular Disease, and COVID-19: A
583 Narrative Review. *Biomedicines* **11**, doi:10.3390/biomedicines11041206 (2023).
- 584 3 Makarova, Y. A. *et al.* Atherosclerosis, Cardiovascular Disorders and COVID-19:
585 Comorbid Pathogenesis. *Diagnostics (Basel)* **13**, doi:10.3390/diagnostics13030478
586 (2023).
- 587 4 Chaves, S. S. *et al.* Global, regional and national estimates of influenza-attributable
588 ischemic heart disease mortality. *EClinicalMedicine* **55**, 101740,
589 doi:10.1016/j.eclinm.2022.101740 (2023).
- 590 5 Kapellos, T. S. *et al.* Human Monocyte Subsets and Phenotypes in Major Chronic
591 Inflammatory Diseases. *Front Immunol* **10**, 2035, doi:10.3389/fimmu.2019.02035 (2019).
- 592 6 Eberhardt, N. *et al.* SARS-CoV-2 infection triggers pro-atherogenic inflammatory
593 responses in human coronary vessels. *bioRxiv*, doi:10.1101/2023.08.14.553245 (2023).
- 594 7 Michel, T., Hentges, F. & Zimmer, J. Consequences of the crosstalk between
595 monocytes/macrophages and natural killer cells. *Front Immunol* **3**, 403,
596 doi:10.3389/fimmu.2012.00403 (2012).
- 597 8 Zou, C. *et al.* CD48 is a key molecule of immunomodulation affecting prognosis in glioma.
598 *Onco Targets Ther* **12**, 4181-4193, doi:10.2147/OTT.S198762 (2019).
- 599 9 Zhou, X. *et al.* Novel Necroptosis-Related Gene Signature for Predicting Early Diagnosis
600 and Prognosis and Immunotherapy of Gastric Cancer. *Cancers (Basel)* **14**,
601 doi:10.3390/cancers14163891 (2022).
- 602 10 Bowman, E. R. *et al.* Macrophage maturation from blood monocytes is altered in people
603 with HIV, and is linked to serum lipid profiles and activation indices: A model for studying
604 atherogenic mechanisms. *PLoS Pathog* **16**, e1008869, doi:10.1371/journal.ppat.1008869
605 (2020).
- 606 11 Schulte-Schrepping, J. *et al.* Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell
607 Compartment. *Cell* **182**, 1419-1440 e1423, doi:10.1016/j.cell.2020.08.001 (2020).
- 608 12 Zhao, G. *et al.* Single-cell RNA sequencing reveals the cellular heterogeneity of
609 aneurysmal infrarenal abdominal aorta. *Cardiovasc Res* **117**, 1402-1416,
610 doi:10.1093/cvr/cvaa214 (2021).
- 611 13 Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.
612 *Innovation (Camb)* **2**, 100141, doi:10.1016/j.xinn.2021.100141 (2021).

- 613 14 Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing
614 biological themes among gene clusters. *OMICS* **16**, 284-287, doi:10.1089/omi.2011.0118
615 (2012).
- 616 15 Dixon, K. J. *et al.* MyD88 is an essential regulator of NK cell-mediated clearance of MCMV
617 infection. *Mol Immunol* **137**, 94-104, doi:10.1016/j.molimm.2021.07.001 (2021).
- 618 16 Maucourant, C. *et al.* Natural killer cell immunotypes related to COVID-19 disease
619 severity. *Sci Immunol* **5**, doi:10.1126/sciimmunol.abd6832 (2020).
- 620 17 Papazafiropoulou, A. & Tentolouris, N. Matrix metalloproteinases and cardiovascular
621 diseases. *Hippokratia* **13**, 76-82 (2009).
- 622 18 Halvorsen, B. *et al.* Activated platelets promote increased monocyte expression of CXCR5
623 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects
624 of CXCL13. *Atherosclerosis* **234**, 352-359, doi:10.1016/j.atherosclerosis.2014.03.021
625 (2014).
- 626 19 Ahmed-Hassan, H. *et al.* Innate Immune Responses to Highly Pathogenic Coronaviruses
627 and Other Significant Respiratory Viral Infections. *Front Immunol* **11**, 1979,
628 doi:10.3389/fimmu.2020.01979 (2020).
- 629 20 Hartana, C. A. *et al.* Immune correlates of HIV-1 reservoir cell decline in early-treated
630 infants. *Cell Rep* **40**, 111126, doi:10.1016/j.celrep.2022.111126 (2022).
- 631 21 Duault, C. *et al.* Activated natural killer cells predict poor clinical prognosis in high-risk B-
632 and T-cell acute lymphoblastic leukemia. *Blood* **138**, 1465-1480,
633 doi:10.1182/blood.2020009871 (2021).
- 634 22 Kamiya, T., Seow, S. V., Wong, D., Robinson, M. & Campana, D. Blocking expression of
635 inhibitory receptor NKG2A overcomes tumor resistance to NK cells. *J Clin Invest* **129**,
636 2094-2106, doi:10.1172/JCI123955 (2019).
- 637 23 Titanji, K. *et al.* Altered distribution of natural killer cell subsets identified by CD56, CD27
638 and CD70 in primary and chronic human immunodeficiency virus-1 infection. *Immunology*
639 **123**, 164-170, doi:10.1111/j.1365-2567.2007.02657.x (2008).
- 640 24 Hong, C. G. *et al.* Oxidized low-density lipoprotein associates with cardiovascular disease
641 by a vicious cycle of atherosclerosis and inflammation: A systematic review and meta-
642 analysis. *Front Cardiovasc Med* **9**, 1023651, doi:10.3389/fcvm.2022.1023651 (2022).
- 643 25 Khatana, C. *et al.* Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced
644 Atherosclerosis. *Oxid Med Cell Longev* **2020**, 5245308, doi:10.1155/2020/5245308
645 (2020).
- 646 26 Wolf, D. & Ley, K. Immunity and Inflammation in Atherosclerosis. *Circ Res* **124**, 315-327,
647 doi:10.1161/CIRCRESAHA.118.313591 (2019).
- 648 27 Flynn, M. C., Pernes, G., Lee, M. K. S., Nagareddy, P. R. & Murphy, A. J. Monocytes,
649 Macrophages, and Metabolic Disease in Atherosclerosis. *Front Pharmacol* **10**, 666,
650 doi:10.3389/fphar.2019.00666 (2019).
- 651 28 Marchio, P. *et al.* Targeting Early Atherosclerosis: A Focus on Oxidative Stress and
652 Inflammation. *Oxid Med Cell Longev* **2019**, 8563845, doi:10.1155/2019/8563845 (2019).
- 653 29 Smedbakken, L. M. *et al.* Increased levels of the homeostatic chemokine CXCL13 in
654 human atherosclerosis - Potential role in plaque stabilization. *Atherosclerosis* **224**, 266-
655 273, doi:10.1016/j.atherosclerosis.2012.06.071 (2012).
- 656 30 Lin, J., Kakkar, V. & Lu, X. Impact of MCP-1 in atherosclerosis. *Curr Pharm Des* **20**, 4580-
657 4588, doi:10.2174/1381612820666140522115801 (2014).
- 658 31 Mouchati, C. *et al.* Increase in gut permeability and oxidized ldl is associated with post-
659 acute sequelae of SARS-CoV-2. *Front Immunol* **14**, 1182544,
660 doi:10.3389/fimmu.2023.1182544 (2023).
- 661 32 Vaccari, M. *et al.* Adjuvant-dependent innate and adaptive immune signatures of risk of
662 SIVmac251 acquisition. *Nat Med* **22**, 762-770, doi:10.1038/nm.4105 (2016).

- 663 33 Liyanage, N. P. *et al.* Antiretroviral therapy partly reverses the systemic and mucosal
664 distribution of NK cell subsets that is altered by SIVmac(2)(5)(1) infection of macaques.
665 *Virology* **450-451**, 359-368, doi:10.1016/j.virol.2013.12.003 (2014).
- 666 34 Palano, M. T. *et al.* When a Friend Becomes Your Enemy: Natural Killer Cells in
667 Atherosclerosis and Atherosclerosis-Associated Risk Factors. *Front Immunol* **12**, 798155,
668 doi:10.3389/fimmu.2021.798155 (2021).
- 669 35 Bonaccorsi, I. *et al.* Symptomatic Carotid Atherosclerotic Plaques Are Associated With
670 Increased Infiltration of Natural Killer (NK) Cells and Higher Serum Levels of NK Activating
671 Receptor Ligands. *Front Immunol* **10**, 1503, doi:10.3389/fimmu.2019.01503 (2019).
- 672 36 Kumar, A. *et al.* SARS-CoV-2 cell entry receptor ACE2 mediated endothelial dysfunction
673 leads to vascular thrombosis in COVID-19 patients. *Med Hypotheses* **145**, 110320,
674 doi:10.1016/j.mehy.2020.110320 (2020).
- 675 37 Weber, C. & Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. *Nat*
676 *Med* **17**, 1410-1422, doi:10.1038/nm.2538 (2011).
- 677 38 Netea, M. G. *et al.* Defining trained immunity and its role in health and disease. *Nat Rev*
678 *Immunol* **20**, 375-388, doi:10.1038/s41577-020-0285-6 (2020).
- 679 39 Chen, J. *et al.* Lp-PLA(2) (Lipoprotein-Associated Phospholipase A(2)) Deficiency Lowers
680 Cholesterol Levels and Protects Against Atherosclerosis in Rabbits. *Arterioscler Thromb*
681 *Vasc Biol* **43**, e11-e28, doi:10.1161/ATVBAHA.122.317898 (2023).
- 682 40 Zureik, M., Beaudoux, J. L., Courbon, D., Benetos, A. & Ducimetiere, P. Serum tissue
683 inhibitors of metalloproteinases 1 (TIMP-1) and carotid atherosclerosis and aortic arterial
684 stiffness. *J Hypertens* **23**, 2263-2268 (2005).
- 685 41 Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the
686 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
687 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* **323**,
688 1239-1242, doi:10.1001/jama.2020.2648 (2020).
- 689 42 Guan, W. J. *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl*
690 *J Med* **382**, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).
- 691 43 Madoiwa, S. Recent advances in disseminated intravascular coagulation: endothelial cells
692 and fibrinolysis in sepsis-induced DIC. *J Intensive Care* **3**, 8, doi:10.1186/s40560-015-
693 0075-6 (2015).
- 694 44 Selathurai, A. *et al.* Natural killer (NK) cells augment atherosclerosis by cytotoxic-
695 dependent mechanisms. *Cardiovasc Res* **102**, 128-137, doi:10.1093/cvr/cvu016 (2014).
- 696 45 Olson, N. C. *et al.* Soluble CD14, Ischemic Stroke, and Coronary Heart Disease Risk in a
697 Prospective Study: The REGARDS Cohort. *J Am Heart Assoc* **9**, e014241,
698 doi:10.1161/JAHA.119.014241 (2020).
- 699